NSE
Lupin LimitedLUPIN
Lupin is a major pharma company strong in US generics and respiratory.
| Key products | Generics, inhalation, biosimilars, APIs; India branded. |
|---|---|
| Geography | US, India, EMEA, APAC. |
| Competitors | Sun Pharma, Cipla, Dr Reddy's. |
AI-generated overview — verify before relying on it.
Net institutional flow
No institutional deals
Institutional buyers
0 in / 0 out
High-impact filings
0 · tilt Neutral
Next corporate action
Dividend - Rs 12 Per Share
ex 2025-07-25
Competitive landscape — the read
vs mapped peers| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | CIPLA | +₹1,527.1 Cr | 39 | — | +1 | +10 | 34 |
| 2 | MANKIND | +₹445.9 Cr | 38 | — | — | — | — |
| 3 | ALKEM | +₹103.5 Cr | 33 | — | — | -2 | 6 |
| 4 | LUPINThis | +₹0 Cr | 4 | — | — | — | — |
| 5 | DRREDDY | +₹0 Cr | 4 | — | — | +14 | 32 |
| 6 | SUNPHARMA | +₹0 Cr | 6 | — | +2 | +9 | 29 |
| 7 | TORNTPHARM | +₹0 Cr | 2 | — | — | — | — |
| 8 | ZYDUSLIFE | +₹0 Cr | 1 | — | — | — | — |
| 9 | AUROPHARMA | +₹0 Cr | 2 | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
Timeline — LUPIN day by day
- 2026-06-08FilingLupin Limited has informed the Exchange regarding a press release dated Jun 08, 2026, titled "Lupin CollaboratPress Release
- 2025-10-14BlockSELL · ₹11.6 CrGOLDMAN SACHS (SINGAPORE) PTE - ODI
- 2025-10-14BlockBUY · ₹11.6 CrGOLDMAN SACHS BANK EUROPE SE - ODI
- 2025-10-13BlockSELL · ₹16.2 CrGOLDMAN SACHS (SINGAPORE) PTE - ODI
- 2025-10-13BlockBUY · ₹16.2 CrGOLDMAN SACHS BANK EUROPE SE - ODI
- 2025-07-25ActionDividend - Rs 12 Per ShareDividend
- 2024-07-16ActionDividend - Rs 8 Per ShareDividend
Merged from deals, filings, corporate actions and news — newest first. Scope the deal/action portion with the period chips below.
Filings that matter
- 2Press ReleaseNeutral
a press release dated Jun 08, 2026, titled "Lupin Collaborates with ERN for Luforbec® (beclometasone/formoterol) pMDI Launch in Spain".
Source PDF →
4 deals · 2025-10-13 → 2025-10-14
| Date | Counterparty | Investor type | Side | Value |
|---|---|---|---|---|
| 2025-10-14 | GOLDMAN SACHS (SINGAPORE) PTE - ODI | HNI / other | SELL | ₹11.6 Cr |
| 2025-10-14 | GOLDMAN SACHS BANK EUROPE SE - ODI | HNI / other | BUY | ₹11.6 Cr |
| 2025-10-13 | GOLDMAN SACHS (SINGAPORE) PTE - ODI | HNI / other | SELL | ₹16.2 Cr |
| 2025-10-13 | GOLDMAN SACHS BANK EUROPE SE - ODI | HNI / other | BUY | ₹16.2 Cr |
4 deals in the selected window — corporate actions are scoped to the same period. ~2 years of history available.
News & chatter on LUPIN
RSS News
0No recent news.
Google News RSS — links open the source.
The Dispatch
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.